Protective effect of VK₂ on glucocorticoid-treated MC3T3-E1 cells

YUE-LEI ZHANG¹,², JUN-HUI YIN¹, HAO DING¹, WEI ZHANG¹, CHANG-QING ZHANG¹ and YOU-SHUI GAO¹

¹Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233; ²Department of Orthopedic Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, P.R. China

Received November 25, 2015; Accepted November 24, 2016

DOI: 10.3892/ijmm.2016.2817

Abstract. Glucocorticoids (GCs) contribute to the increased incidence of secondary osteoporosis and osteonecrosis, and medications for the prevention and treatment of these complications have been investigated for many years. Vitamin K₂ (VK₂) has been proven to promote bone formation both in vitro and in vivo. In this study, we examined the effects of VK₂ on dexamethasone (DEX)-treated MC3T3-E1 osteoblastic cells. We observed that VK₂ promoted the proliferation and enhanced the survival of dexamethasone-treated MC3T3-E1 cells. In addition, VK₂ upregulated the expression levels of osteogenic marker proteins, such as Runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP) and osteocalcin, which were significantly inhibited by dexamethasone. On the whole, our findings indicate that VK₂ has the potential to antagonize the effects of GCs on MC3T3-E1 cells, and may thus prove to be a promising agent for the prevention and treatment of GC-induced osteoporosis and osteonecrosis.

Introduction

Glucocorticoids (GCs) have been extensively used in the treatment of a variety of diseases, due to their potent anti-inflammatory effects. However, the long-term and excessive use of GCs is one of the most common causes of atraumatic osteonecrosis of the femoral head and likely increases the incidence of secondary osteoporosis (1). These complications are partially attributed to modifications in the bioactivity of bone marrow-derived stem cells, osteoblasts/osteocytes and osteoclasts (2-4). Previous studies have indicated that GCs antagonize Runt-related transcription factor 2 (Runx2) during the osteoblast differentiation of mesenchymal cells and inhibit the osteogenesis of bone marrow-derived stem cells (3,5).

GCs have also been reported to directly suppress the osteogenic differentiation of osteoblasts (6), induce osteoblast and osteocyte apoptosis, and decrease the number of bone-forming cells (7-9). Another study indicated that GC-induced bone resorption is caused by a direct effect of the GCs on extending the lifespan of osteoclasts (10).

Vitamin K (VK), whose active form has been demonstrated to be a coenzyme for γ-carboxylase, plays an important role in bone metabolism (11,12). There are two types of VK in nature, VK₀ (phyloquinone) and VK₁ (menatetrenone). VK₁ is a single compound and is primarily found in plants, while VK₀ is a series of vitamins with multiple isoprene units at the 3-position of the naphthoquinone and is named according to the number of these prenyl units (13,14). Studies have indicated that VK₂ has a more pronounced osteoprotective effect than VK₁ (15,16). In addition to the γ-carboxylation of osteocalcin (OCN), VK₂ has been proven to promote osteoblast proliferation (13) and the osteoblast-to-osteocyte transition in vitro (15,17-19), including OCN accumulation in the extracellular matrix, the upregulation of Runx2 and alkaline phosphatase (ALP), and the transcription of osteogenic genes. Additional studies also revealed the osteoprotective effects of VK₂ in vivo. Akiyama et al and Iwamoto et al observed that VK₂ prevented bone loss in rats with ovariectomy or sciatic neurrectomy (20,21); bone healing was also promoted in the osteotomy model in the study by Iwamoto et al (22). Based on these findings, VK₂ has been used in the treatment of osteoporosis in Asian countries for a number of years (23,24).

Several studies have reported the protective effects of VK₂ on prednisolone-treated rats (22,25,26); however, few studies have reported similar findings in vitro. Thus, the purpose of this study was to examine the effects of VK₂ on GC-treated osteoblasts.

Materials and methods

Chemicals. The cell culture medium, Dulbecco’s modified Eagle’s medium (DMEM; low glucose, 1 g/l), was obtained from HyClone, Logan, UT, USA. Fetal bovine serum (FBS) and the penicillin-streptomycin solution (10,000 U/ml penicillin; 10 mg/ml streptomycin) were purchased from Gibco Laboratories (Grand Island, NY, USA). VK₂, L-ascorbic acid and β-glycerophosphate disodium salt hydrate were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Dexamethasone (DEX) was obtained from Sigma and was...
used at a concentration of 1 µM in all the experiments in this study. VK₃ was dissolved in anhydrous ethanol and all other chemicals were dissolved in PBS.

**Cell culture.** Mouse osteoblastic MC3T3-E1 cells (GNM15) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (10 µg/ml). Osteogenic differentiation was induced in DMEM supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (10 µg/ml), L-ascorbic acid (50 µg/ml) and β-glycerophosphate disodium salt hydrate (10 mM). All cells were cultured at 37°C in a humidified atmosphere containing 5% CO₂.

**Cell proliferation assay.** The MC3T3-E1 cells (5,000/well) were plated in 96-well plates and incubated overnight. Ten microliters of Cell Counting Kit-8 (CCK-8) solution were then added to 100 µl of culture medium and the wells were incubated for an additional 2 h. The absorbance values at 450 nm measured using a microplate reader (Bio-Rad, Hercules, CA, USA) were recorded as the initial values (0 day), and the cells were then treated with both DEX and various concentrations of VK₃ (10⁻⁵, 10⁻⁶ and 10⁻⁷ M), with medium changes every 2 days. CCK-8 detection was performed again at appropriate time points (48, 96 and 144 h) following incubation with the different chemicals, and the absorbance values were recorded and analyzed.

**Cell apoptosis and viability assay.** The Annexin V-FITC cell apoptosis detection kit (Beyotime Biotechnology, Shanghai, China) was used to detect cell apoptosis. The MC3T3-E1 cells were incubated with or without DEX and various concentrations of VK₃ (10⁻⁵, 10⁻⁶ and 10⁻⁷ M) for 6 days, collected, resuspended in 200 µl of Annexin V-FITC and 10 µl of propidium iodide, and incubated for 20 min at room temperature. Subsequently, flow cytometry was used to evaluate the number of apoptotic cells. The early apoptotic cells are labeled green and the dead and late apoptotic cells are labeled red, while the live cells are not stained. Trypan blue staining was performed to evaluate cell viability. The MC3T3-E1 cells were treated with both DEX and various concentrations of VK₃ (10⁻⁵, 10⁻⁶ and 10⁻⁷ M) in FBS-free medium for 6 days and then collected. Ten microliters of trypan blue (Invitrogen, Carlsbad, CA, USA) were mixed with 10 µl of the cell suspension, and 10 µl of the mixture were then added to the cell counting plate. The cell death rates were automatically calculated with a cell counter (Invitrogen). A ReadyProbes Cell Viability Imaging kit (Life Technologies, Gaithersburg, MD, USA) was also used to detect cell viability at 6 days after the MC3T3-E1 cells were incubated under the different conditions. The blue dye stained all living cells, and the green dye stained the dead cells.

**Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** The cells were cultured in osteogenic differentiation medium and treated with DEX or DEX with various concentrations of VK₃ (10⁻⁵, 10⁻⁶, and 10⁻⁷ M). Total RNA was extracted using TRIzol reagent (Invitrogen) at 1, 3 and 7 days following treatment, and the RNA was then reverse transcribed into cDNA using the EasyScript one-step gDNA Removal and cDNA Synthesis SuperMix (TransGen Biotech Co., Ltd., Beijing, China), according to the manufacturer’s instructions. RT-qPCR for ALP, OCN and Runx2 was performed using the TransStart Tip Green qPCR SuperMix (TransGen Biotech Co., Ltd.) with ABI Prism 7900 (Invitrogen). The reaction conditions were 1 cycle of 95°C for 30 sec and 40 cycles of 95°C for 5 sec and 60°C for 30 sec. Subsequently, a 65-95°C solubility curve was constructed. The relative amount of each mRNA was normalized to the β-actin mRNA. The primer sequences of each cDNA are presented in Table I.

**Determination of ALP activity and staining.** To assay the ALP activity in the cells subjected to the different treatments, the total protein was harvested at 1, 3 and 7 days after the different treatments, as described above. ALP activity was evaluated using the ALP assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China), according to the manufacturer’s instructions. The values were measured at 520 nm and normalized to the protein concentration determined using the BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA). In addition, ALP staining was performed 7 days following incubation with the conditioning medium using the BCIP/NBT ALP Color Development kit (Beyotime Biotechnology), according to the manufacturer’s instructions.

**Alizarin Red staining.** Following incubation with DEX or DEX plus various concentrations of VK₃ (10⁻⁵, 10⁻⁶, and 10⁻⁷ M), the cell cultures were rinsed 3 times with PBS, fixed with 4% paraformaldehyde for 30 min, and then stained with Alizarin Red (Beyotime Biotechnology) for a further 30 min. The cultures were then evaluated under a light microscope (CKX31; Olympus, Tokyo, Japan).

**Immunofluorescence staining for Runx2 and OCN.** Following 7 days of incubation with the different conditioning media, the MC3T3-E1 cells were fixed with 4% paraformaldehyde for 20 min, treated with 0.1% Triton X-100 for 15 min, and blocked with 10% FBS for 30 min at 37°C. The cells were then incubated with a rabbit anti-Runx2 monoclonal antibody (1:1,000 dilution; #12556; Cell Signaling Technology, Danvers, MA, USA) or an anti-OCN antibody (1:200 dilution; AB10911; Millipore, Billerica, MA, USA), followed by an anti-rabbit Alexa Fluor 488 secondary antibody (1:500 dilution; A32731; Invitrogen) for a further 30 sec, rinsed with PBS and then examined under a fluorescence microscope (Leica DM IL LED; Leica, Wetzlar, Germany).

**Western blot analysis.** To examine the effects of DEX or DEX and VK₃ on the differentiation of the MC3T3-E1 cells, total protein was harvested from the cells cultured in the osteogenic medium described above for 1, 3 and 7 days. The protein concentrations were measured using the BCA protein assay kit (Thermo Fisher Scientific). The protein samples were then separated on a 10% SDS-PAGE gel and transferred onto a PVDF membrane. The membrane was blocked with 5% BSA and incubated with the primary antibodies overnight at 4°C, followed by incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h. After rinsing 3 times with PBST, the membrane was scanned in an Odyssey scanner (Li-COR Biotechnology, USA).
Biosciences, Lincoln, NE, USA). The antibodies used for the western blot analysis were as follows: monoclonal rabbit anti-rat GAPDH antibody (1:1,000 dilution; #2118), monoclonal rabbit anti-rat Runx2 antibody (1:1,000 dilution; #12556), and an HRP-conjugated rat anti-rabbit antibody (1:2,000 dilution; #7074) (all from Cell Signaling Technology, Danvers, MA, USA). The bands were quantified using Quantity One software and normalized to GAPDH.

Enzyme-linked immunosorbent assay (ELISA) for OCN in the media.

Following incubation in the conditioning medium for 1, 3 and 7 days, the MC3T3-E1 cells were incubated with regular medium for a further 24 h. The media were then harvested and the concentrations of OCN in the media were detected using an ELISA kit (Mlbio, Shanghai, China); the values were normalized to the total protein concentration, which was determined using a BCA kit (Invitrogen).

Statistical analysis. SPSS 20.0 software (Microsoft, SPSS, Inc., Chicago, IL, USA) was used to analyze the values in each group. All the experiments in this study were performed in triplicate and the data are expressed as the means and standard deviation (SD). A statistical comparison of the data between the groups was performed using one-way analysis of variance (ANOVA) with a Student-Newman-Keuls (SNK) post hoc test. A P-value <0.05 was considered to indicate a statistically significant difference.

Table I. Sequences of primers used for RT-qPCR.

| Gene     | Forward primer                  | Reverse Primer                  |
|----------|--------------------------------|--------------------------------|
| Runx2    | TGGCCGGGGAATGAGAAGAC           | TGAAACTCTTGCTCGTCGCG           |
| ALP      | CACTCTGTCCCGTTGTC             | TTGACGTTCCGATCTCCTGAC         |
| OCN      | TCTGACAAAGCCTTCTGATCCA       | AGCCCCTCTGCAGGTCACTAGA        |
| β-actin  | GTCGAGTCGCGTCACC             | GTCATCCATGCGAACTGTT          |

Runx2, Runt-related transcription factor 2; ALP, alkaline phosphatase; OCN, osteocalcin.

Results

VK₂ promotes MC3T3-E1 cell proliferation and enhances MC3T3-E1 cell survival in the DEX-treated cultures. A CCK-8 assay was performed at 48, 96 and 144 h following treatment with DEX alone or with DEX and VK₂. The results revealed that MC3T3-E1 cell proliferation was significantly suppressed at 96 and 144 h by DEX, although no significant change was observed at 48 h. However, the addition of VK₂ promoted cell proliferation at these 3 time points, particularly following treatment with 10⁻⁶ and 10⁻⁷ M VK₂. We did not observe a dose-dependent effect of VK₂ (Fig. 1A).

The results of cell apoptosis assay indicated that VK₂ inhibited apoptosis and enhanced the survival of the DEX-treated cells, which was also demonstrated by trypan blue staining. In this experiment, only 65.3% of the MC3T3-E1 cells in the DEX group survived after being treated with DEX in FBS-free medium for 6 days, while significantly more cells survived in the other groups. Cell viability imaging also yielded similar results (Fig. 1B-D).

VK₂ improves the osteogenic differentiation potential of DEX-treated MC3T3-E1 cells. To verify whether VK₂ enhances the osteogenic differentiation potential of DEX-treated MC3T3-E1 cells, we also detected the mRNA expression levels of both early and mature osteogenic markers in the MC3T3-E1 cells. The results revealed that, following incubation, the
mRNA levels of Runx2, ALP and OCN were downregulated by DEX and upregulated by VK_{2}, particularly following treatment with 10^{-6} M VK_{2} (Fig. 2).

**VK_{2} upregulates Runx2 expression in DEX-treated MC3T3-E1 cells.** We performed immunofluorescence staining and western blot analysis to detect the expression of Runx2, an early osteogenic marker. We observed that the Runx2 level in the DEX-treated MC3T3 cells was significantly decreased, while the Runx2 protein levels were significantly upregulated in the presence of VK_{2}, particularly 10^{-6} M VK_{2} (Fig. 3).

**VK_{2} promotes ALP expression in the DEX-treated MC3T3-E1 cells.** Following 7 days of incubation with DEX or DEX and various concentrations of VK_{2}, we performed ALP staining to detect osteogenesis in the MC3T3-E1 cells. As shown in Fig. 4, treatment with 10^{-6} M DEX markedly decreased the number of ALP-positive cells, while VK_{2} antagonized this effect, showing more bluish violet-coloured cells. ALP activity was also detected following 1, 3 and 7 days of incubation. The results revealed that ALP activity increased over time. The MC3T3-E1 cells in the DEX group displayed less ALP activity than those of the control group, particularly following treatment with 10^{-6} M VK_{2} on day 7 (Fig. 4).

**VK_{2} promotes OCN expression in the DEX-treated MC3T3-E1 cells.** OCN is a mature stage osteogenic marker; therefore, the OCN levels in the media of the MC3T3-E1 cells treated with DEX and VK_{2} were detected on days 1, 3 and 7. The results revealed that the OCN levels in the media increased over time. The DEX-treated MC3T3-E1 cells secreted evidently less OCN than the controls at all time points, while the MC3T3-E1 cells treated with DEX and VK_{2} had more OCN in the media, particularly the cells treated with 10^{-6} M VK_{2} (Fig. 5). We also detected OCN expression in the MC3T3-E1 cells using immunofluorescence staining, and observed less OCN expression in the DEX-treated MC3T3-E1 cells and increased OCN expression in the VK_{2} groups. In addition, Alizarin Red staining revealed a similar antagonism of VK_{2} toward the DEX-treated MC3T3-E1 cells (Fig. 5).

**Discussion**

GC-induced osteoporosis greatly increases the risk of fracture, and pharmacological therapy is recommended as soon as possible and has been studied for many years (27). VK_{2} has been reported to be a promising therapy for GC-induced osteoporosis (28). Studies have indicated that VK_{2} inhibits bone loss and increases bone formation in GC-treated rats (25,29). Clinical studies have also reported increased serum levels of carboxylated OCN and lumbar bone mass volume in GC-treated patients (26,30). This study further confirmed the protective effects of VK_{2} against GC-induced damage in osteoblasts in vitro.

Several studies have indicated that GCs inhibit osteoblast proliferation in vivo (31,32), and VK_{2} has also been reported to promote osteoblast proliferation (13). In this study, we further confirmed the proliferative-promoting effect of VK_{2} on GC-treated MC3T3-E1 cells. This effect may be related to growth arrest-specific gene 6 (Gas6), which is a VK-dependent protein that is involved in cell proliferation by activating Axl (33,34). GC-induced osteoblast apoptosis has been clearly demonstrated in both in vivo and clinical studies (7,35). In this study, we observed significant apoptosis of the DEX-treated MC3T3-E1 cells and an anti-apoptotic effect of VK_{2}. Studies have demonstrated that VK_{2} has some biological effects as a co-factor, including anti-apoptotic effects in erythroid progenitors (36), maintaining endothelial cell survival (37) and protecting neurons from methylmercury-induced cell death (38). The anti-apoptotic effects of VK_{2} are believed to be related to its role as an electron carrier in the regulation of mitochondrial function (39).

The critical role of Runx2 in osteoblasts has been well described by previous studies (40,41). Runx2 is a master transcription factor in osteoblast differentiation and bone formation, and strongly impacts the expression of osteoblast marker genes and related proteins, such as ALP. The study by Koromila et al demonstrated that GC markedly antagonized Runx2 and Runx2-mediated ALP activity in mesenchymal cells (3). In this study, we also observed that Runx2 was downregulated by GCs in osteoblastic cells, similar to a previous study by Kim et al (6). Furthermore, we observed a higher expression of Runx2 in the MC3T3-E1 cells treated
with both GCs and VK₂, which indicated that VK₂ promoted the osteoblast differentiation of GC-treated osteoblastic cells partly by upregulating Runx2.

OCN is a non-collagenous, VK-dependent protein that is secreted in the late stage of osteoblast differentiation. One role of VK₂ in bone metabolism is to act as a coenzyme for the
γ-carboxylation of OCN, which combines with hydroxyapatite to ultimately promote bone mineralization (42). With the exception of its role as a regulator of bone mineralization, OCN has also been reported to regulate bone remodeling by modulating osteoblast and osteoclast activity (43). Runx2 has been recognized as a key regulator of OCN transcription, and both Runx2 and OCN transcription are inhibited by GCs (3,43). Studies have also shown that VK2 enhances OCN accumulation in human osteoblasts (43,19). In this study, we observed an evident downregulation in the proteins levels of Runx2 and OCN in the DEX-treated MC3T3-E1 cells and further confirmed the stimulatory effect of VK2 on osteoblast differentiation. Furthermore, we observed the upregulated expression of osteogenesis-related genes in the MC3T3-E1 cells treated with DEX and VK2; this may be attributed to the transcriptional effect of VK2, as VK2 can activate steroid and xenobiotic receptor (SXR) and regulate the transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells (44-46).

Studies have demonstrated that treatment with 10⁻⁵ M VK2 alone promotes mineralization and increases the Ca²⁺ concentrations more effectively than lower concentrations (17,18). However, in this study, we found that treatment with 10⁻⁶ M VK2, which was comparable to the serum concentrations in patients treated with VK (47), exerted the most effective protection against DEX. Some other studies have observed similar results, where 10⁻⁶ M VK2 had a stimulatory effect on colony formation and the proliferation of hematopoietic progenitors, producing fewer apoptotic cells than those treated with 10⁻⁵ M VK2 (36). Koshihara and Hoshi (19) observed more OCN in the medium of cells treated with 0.5 µM and 1.5 µM VK2, and OCN release in the medium was significantly enhanced by 0.5 µM VK2 in the presence of 1.25 (OH)₂-D3. Therefore, we speculate that 10⁻⁶ M VK2 may be the most appropriate concentration to antagonize DEX in vitro.

In conclusion, in this study, we demonstrated that VK2 promoted osteoblast proliferation and osteogenic differentiation, inhibited cellular apoptosis and enhanced cellular survival, supporting the view that VK2 is a promising option for the prevention and treatment of GC-induced osteoporosis and osteonecrosis.

Acknowledgements

This study was funded by the National Natural Science Foundation of China (no. 81301572) and the SMC-Chen Xing Plan for Splendid Young Teachers of Shanghai Jiao Tong University.

References

1. Kim BY, Yoon HY, Yun SI, Woo ER, Song NK, Kim HG, Jeong SY and Chung YS: In vitro and in vivo inhibition of glucocorticoid-induced osteoporosis by the hexane extract of Poncirus trifoliata. Phytother Res 25: 1000-1010, 2011.
2. Weinstein RS: Glucocorticoid-induced osteonecrosis. Endocrine 41: 183-190, 2012.
3. Koromila T, Baniwal SK, Song YS, Martin A, Xiong J and Frenkel B: Glucocorticoids antagonize Runx2 during osteoblast differentiation in cultures of ST2 pluripotent mesenchymal cells. J Cell Biochem 115: 27-33, 2014.
4. Kerachian MA, Séguin C and Harvey EJ: Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol 114: 121-129, 2009.

Figure 5. Protein expression of osteocalcin (OCN) and Alizarin Red staining. (A) Immunofluorescence staining of the MC3T3-E1 cells after a 7-day incubation with dexamethasone (DEX) or DEX and various concentrations of vitamin K₂ (VK₂). (B) Levels of OCN secretion from the MC3T3-E1 cells. VK₂ markedly promoted increased OCN secretion by the MC3T3-E1 cells treated with 10⁻⁵ M DEX. (C) Alizarin Red staining of the MC3T3-E1 cells that were induced for 7 days. Increased numbers of calcified nodules were observed in the DEX + VK groups than in the DEX group, although they were still fewer than the control group (P<0.05, significant difference vs. the DEX group).
5. Tan G, Kang PD and Pei FX: Glucocorticoids affect the metabolism of bone marrow stromal cells and lead to osteonecrosis of the femoral head: a review. Chin Med J (Engl) 125: 134-139, 2012.
6. De Groot LC, Van Hall GN, Van der Stappen AG, van der Knaap WS: The effect of oral vitamin K2 on the development of prothrombin factor X deficiency. Thromb Haemost 90: 336-341, 2003.
7. O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC and Weinstein RS: Glucocorticoids act directly on osteoblasts to modulate their apoptosis and reduce bone formation and strength. Endocrinology 145: 1835-1841, 2004.
8. Weinstein RS, Jilka RL, Parfitt AM and Manolagas SC: Inhibition of osteoblastogenesis and proliferation of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274-282, 1998.
9. Yun SL, Yoon HY, Jeong SY and Chung YS: Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase-3β and extracellular signal-regulated kinase 1/2. J Bone Miner Res 12: 431-438, 1997.
10. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM and Manolagas SC: Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109: 1041-1048, 2002.
11. Hamidi MS, Gajic-Veljanoski O and Cheung AM: Vitamin K promotes mineralization, reversal of mineralization defect, and apoptosis of osteoblasts by microRNA-199a targeting of WNT signaling. J Mol Endocrinol 54: 325-337, 2015.
12. Stransfeld J, Dahlbäck B and Hafizi S: Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts. Biochem Biophys Res Commun 339: 871-878, 2006.
13. Terada K, Hayashi T, Saito M, Ohtani G, Takeda T, Hori H, Inoue T, Sugiyama T, Matsubara T, Kawai S and Furukawa S: Apoptosis - a significant cause of bone cell death in osteonecrosis of the femoral head. J Bone Joint Surg Br 86: 1209-1213, 2004.
14. Sakaue M, Iwamoto S and Takeyama H: Vitamin K1 promotes mineralization, reversal of mineralization defect, and apoptosis of both myoblast and erythroid lineages. Eur J Haematol 85: 538-548, 2010.
15. Hegarty JM, Yang H and Chi NC: UBIAD1-mediated vitamin K synthesis is required for vascular endothelial cell survival and development. Development 133: 1713-1723, 2006.
16. Sakaue M, Mori N, Okazaki M, Kadowaki E, Kaneko T, Hemmi N, Sekiguchi H, Maki T, Ozawa A, Hara S, et al: Vitamin K has the potential to protect neurons from methylmercury-induced cell death in vitro. J Neurosci Res 89: 1052-1058, 2011.
17. Vor S, Esposito G, Edirisinghe JN, Vilain S, Haddad DM, Slabbaert JR, Van Meensel S, Schaap O, De Strooper B, Meganathan R, et al: Vitamin K is a mitochondrial electron carrier that rescues p53-deficiency. Science 336: 1306-1310, 2012.
18. Atkinson PC, Gabel PJ, Cottle T, Gooding SR, Smith EE, Li Q, Sanchez-Tapias J, Castle M, Abreu M, et al: GLA improves bone density and reduces fractures in ovariectomized rats. J Bone Miner Res 28: 1520-1528, 2013.
19. Tanaka T, Sato Y, Hori T, Ohashi T, Iwamoto S, Ohtani G, Inoue T, Sugiyama T, Matsubara T, Kawai S and Furukawa S: Vitamin K-dependent carboxylation of osteocalcin affects the efficacy of teriparatide (PTH(1-34)) for skeletal repair. Bone 64: 108-113, 2014.
20. Iwamoto T, Takahata M, Takeda T, Sato Y and Yeh JK: Effects of vitamin K1 on cortical and cancellous bone mass, cortical osteocyte and lacunar system, and porosity in sciatric neurectomized rats. Calcif Tissue Int 88: 254-262, 2010.
21. Iwamoto T, Seki A, Sato Y, Matsumoto H, Takeda T and Yeh JK: Vitamin K promotes bone healing in a rat femoral osteotomy model with or without glucocorticoid treatment. Calcif Tissue Int 86: 234-241, 2010.
22. Iwashita K, Takachah P, Mogami K, Igarashi K, Uchida M, Tsuchiya K, Honda M and Kato M: Effects of vitamin K supplementation on the expression of osteocalcin and osteopontin in rat femoral head: a review. Chin Med J (Engl) 125: 134-139, 2012.
23. Koitaya N, Sekiguchi M, Tousen Y, Nishide Y, Morita A, Yamauchi J, Gando Y, Miyachi M, Aoki M, Komatsu M, et al: Low-dose vitamin K (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women. J Bone Miner Metab 32: 142-150, 2014.
24. Koitaya N, Sato Y, Kikuchi M, Yamauchi J, Hashizume E, Morioka K, Miyachi M, Sasaki S and Ishimi Y: Effect of low dose vitamin K2 (MK-4) supplementation on bio-indices in postmenopausal Japanese women. J Nutr Sci Vitaminol (Tokyo) 55: 15-21, 2009.
25. Kan K, Akiyama Y, Ohkawa I and Tajima T: Effects of menaquinone-4 on prednisolone-induced bone loss in rats. Bone 14: 813-818, 1993.
26. Sasaki N, Kusano E, Takahashi A, Ando Y, Yano K, Tsuda E and Asano Y: Vitamin K inhibits glucocorticoid-induced bone loss partly by inhibiting the reduction of osteoprotegerin (OPG). J Bone Miner Metab 23: 41-47, 2005.